To test this hypothesis, five CRC cell lines were treated with U0126, a MEK/ERK inhibitor, and mithramycin A (MMA), an SP1 inhibitor that not only attenuates the binding of SP1 to DNA but also promotes the proteasome‐dependent degradation of SP1 (Figure S8A, Supporting Information). This evidence concerns the gene MAPK1 and colorectal carcinoma.